Cipla

Lanreotide

Manufacturer:

Cipla

Lanreotide HCPCS:

J1932

HCPCS Code Descriptor:

Injection, lanreotide, (cipla), 1 mg

Category:

J Code

Lanreotide NDCs:

69097-0870-67

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Package Type:

Syringe

Route of Administration:

Subcutaneous

Lanreotide CPT Codes:

Potential CPT administration codes for Lanreotide can be found at the following link.

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Lanreotide:

Lanreotide is an Oncology drug manufactured by Cipla and administered via the Subcutaneous route of administration. The J Code: J1932 is aligned to the drug Lanreotide.

Lanreotide is an injectable medication often used to treat acromegaly, a type of hormone disorder that causes too much growth hormone in the body. It may also given to patients with neuroendocrine tumors, or NETS, a type of tumor that starts in a neuroendocrine system, the hormone center of the body. Lanreotide contains a synthetic version of somatostatin, a naturally occurring hormone in your body. Lanreotide is thought to work by supplementing the naturally occurring somatostatin in the body, which can help to regulate and decrease other types of hormones.

ACCESS PRICING AND MORE BY REGISTERING

J1932 Added Date:

October 1, 2022

J1932 Effective Date:

October 1, 2022

J1932 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Lanreotide billing and coding information.
Lanreotide patient assistance information can be found through Ipsen Cares at the URL: http://www.ipsencares.com/
Lanreotide prescribing information can be found at the link below:
Information regarding Lanreotide’s side effects can be found at MedlinePlus

BuyandBill.com Drug Alert: